Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3
| Indexado |
|
||||
| DOI | 10.1002/ART.39637 | ||||
| Año | 2016 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Abstract
Conclusion. The association of an increase in PR3-ANCA level with the risk of subsequent relapse is partially affected by the PR3-ANCA detection methodology, disease phenotype, and remission induction treatment. An increase in PR3-ANCA level during complete remission conveys an increased risk of relapse, particularly severe relapse, among patients with renal involvement or alveolar hemorrhage and those treated with rituximab. Serial measurements of PR3-ANCA may be informative in this subset of patients, but the risk of relapse must be weighed carefully against the risks associated with therapy.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Fussner, Lynn A. | Mujer |
Mayo Clin - Estados Unidos
Mayo Fdn Med Educ & Res - Estados Unidos Mayo Clinic - Estados Unidos |
| 2 | Hummel, Amber M. | Mujer |
Mayo Clin - Estados Unidos
Mayo Fdn Med Educ & Res - Estados Unidos Mayo Clinic - Estados Unidos |
| 3 | Schroeder, Darrell R. | Hombre |
Mayo Clin - Estados Unidos
Mayo Fdn Med Educ & Res - Estados Unidos Mayo Clinic - Estados Unidos |
| 4 | SILVA-LABRA, FRANCISCO ANDRES | Hombre |
Universidad del Desarrollo - Chile
|
| 5 | Cartin-Ceba, Rodrigo | Hombre |
Mayo Clin - Estados Unidos
Mayo Fdn Med Educ & Res - Estados Unidos Mayo Clinic - Estados Unidos |
| 6 | Snyder, Melissa R. | Mujer |
Mayo Clin - Estados Unidos
Mayo Fdn Med Educ & Res - Estados Unidos Mayo Clinic - Estados Unidos |
| 7 | Hoffman, Gary S. | Hombre |
Cleveland Clin Fdn - Estados Unidos
Cleveland Clinic Foundation - Estados Unidos |
| 8 | Kallenberg, Cees G. M. | Hombre |
Univ Groningen - Países Bajos
University of Groningen - Países Bajos Rijksuniversiteit Groningen - Países Bajos |
| 9 | Langford, Carol A. | Mujer |
Cleveland Clin Fdn - Estados Unidos
Cleveland Clinic Foundation - Estados Unidos |
| 10 | Merkel, Peter A. | Hombre |
UNIV PENN - Estados Unidos
University of Pennsylvania - Estados Unidos |
| 11 | Monach, Paul A. | Hombre |
BOSTON UNIV - Estados Unidos
VA Boston Healthcare Syst - Estados Unidos Boston University - Estados Unidos Boston University Medical Center - Estados Unidos |
| 12 | Seo, Philip | Hombre |
Johns Hopkins Univ - Estados Unidos
Johns Hopkins University - Estados Unidos |
| 13 | Spiera, Robert F. | Hombre |
Hosp Special Surg - Estados Unidos
Hospital for Special Surgery - New York - Estados Unidos |
| 14 | St Clair, E. William | - |
Duke Univ - Estados Unidos
|
| 14 | William, E. | - |
Duke University Medical Center - Estados Unidos
|
| 15 | Tchao, Nadia K. | Mujer |
Immune Tolerance Network - Estados Unidos
|
| 16 | Stone, John H. | Hombre |
MASSACHUSETTS GEN HOSP - Estados Unidos
Massachusetts General Hospital - Estados Unidos |
| 17 | Specks, Ulrich | Hombre |
Mayo Clin - Estados Unidos
Mayo Fdn Med Educ & Res - Estados Unidos Mayo Clinic - Estados Unidos |
| 18 | Rituximab ANCA-Associated Vasculit | Corporación |
| Fuente |
|---|
| NIH |
| National Institute of Allergy and Infectious Diseases |
| National Center for Advancing Translational Sciences |
| Genentech |
| National Center for Research Resources |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases |
| NIH (National Center for Advancing Translational Sciences Clinical and Translational Science Award [CTSA]) |
| Juvenile Diabetes Research Foundation |
| Biogen Idec |
| Immune Tolerance Network (NIH) |
| National Institute of Allergy and Infectious Diseases, NIH |
| Arthritis Foundation |
| Agradecimiento |
|---|
| Supported by the NIH (National Center for Advancing Translational Sciences Clinical and Translational Science Award [CTSA] UL1-TR-000135). Enzyme-linked immunosorbent assay kits for antineutrophil cytoplasmic antibody (ANCA) testing were provided by Euroimmun (Lubeck, Germany). Data for the current study were obtained from the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) trial, which was performed with the support of the Immune Tolerance Network (NIH contract N01-AI-15416, protocol number ITN021AI), an international clinical research consortium headquartered at the University of California and supported by the National Institute of Allergy and Infectious Diseases, NIH, and the Juvenile Diabetes Research Foundation. Genentech and Biogen Idec provided the study medications and partial funding for the RAVE trial. At the Mayo Clinic and Foundation, Johns Hopkins University, Boston University, and the Cleveland Clinic, the RAVE trial was supported by the NIH (Mayo Clinic: National Center for Research Resources CTSA 1-UL1-RR-024150-01; Johns Hopkins University: National Center for Research Resources CTSA UL1-RR-025005 and career development awards K23-AR-052820 to Dr. Seo and K24-AR-049185 to Dr. Stone; Boston University: National Center for Research Resources CTSA UL1-RR-025771, grant M01-RR-00533, and career development award K24-AR-02224 to Dr. Merkel; Cleveland Clinic: National Center for Advancing Translational Sciences grant UL1-TR-000439). The RAVE trial at Boston University was also supported by the Arthritis Foundation (Investigator Award to Dr. Monach). |
